glp 1 approved for cardiovascular disease GLP-1 Receptor Agonists the Reduction of Atherosclerotic Risk in Patients With Type 2 Diabetes Cardiovascular disease continuum-GLP-1 action. Adapted

Tirzepatide is a promising drug withdual-acting glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor activation that has revolutionized the treatment of type 2 diabetesmellitus (T2DM) as an adjunct to ...

Compared with SGLT-2 inhibitor use, GLP-1 receptor agonist use was not associated with an increased risk of pulmonary aspiration (pooled risk ratio 0.98, 95% CI 0.73 to 1.31), although it was associated with a higher risk for discontinuation of endoscopy (1.99, 1.56 to 2.53)

A 2026 case report describes a 34-year-old man with obesity and alcohol use disorder whose semaglutide treatment for weight loss was associated with a marked drop in drinking over 10 months, with his AUDIT score falling from 27 to 7 and alcohol use dropping from about 15 drinks per week to half a beer per month

Exploring the link between semaglutide and fertility

Supporting natural GLP-1 activity can make a significant difference in energy levels, weight management, and overall wellness

The findings indicate that HFpEF is associated with various comorbidities, such as obesity, diabetes mellitus, and hypertension, which contribute to endothelial dysfunction